RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis-Reference-Cited by-同舟云学术

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Published:2016-04-01 Issue:5 Volume:15 Page:946-957
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Brünker Peter,Wartha Katharina,Friess Thomas,Grau-Richards Sandra,Waldhauer Inja,Koller Claudia Ferrara,Weiser Barbara,Majety Meher,Runza Valeria,Niu Huifeng,Packman Kathryn,Feng Ningping,Daouti Sherif,Hosse Ralf J.,Mössner Ekkehard,Weber Thomas G.,Herting Frank,Scheuer Werner,Sade Hadassah,Shao Cuiying,Liu Bin,Wang Peng,Xu Gary,Vega-Harring Suzana,Klein Christian,Bosslet Klaus,Umaña Pablo

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Better safe than sorry: dual targeting antibodies for cancer immunotherapy;Biological Chemistry;2024-02-01

2. A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK;The AAPS Journal;2024-01-02

3. Cancer-associated fibroblasts in neoadjuvant setting for solid cancers;Critical Reviews in Oncology/Hematology;2024-01

4. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer;Cancer Cell;2024-01

5. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment;Frontiers in Immunology;2023-12-01